BIOPOLIS_Probiotic for Celiacs
Bifidobacterium longum ES1 is an internationally patented probiotic bacterial strain. It was originally isolated in 2007 from a three-month-old, healthy breastfed child by researchers at the Institute of Agrochemistry and Food Technology, Spanish National Research Council (IATA-CSIC).
Then in 2008, studies in a human blood-cell model showed this strain was able to generate an anti-inflammatory response to gluten peptides. Furthermore, it was found to partially inhibit the growth of pathogenic bacteria isolated from the faeces of celiac disease patients. Taken together, these properties were of extreme interest, thus further scientific studies were undertaken.
As the clinical trials advanced during early 2012, BIOPOLIS scientists began to set up the industrial-scale production strain ES1. This was a complex process, requiring optimisation at laboratory scale first, then at the pilot plant and finally at industrial scale.
Scientists at the dairy company Central Lechera Asturiana, who also participated in the CENIT-SENIFOOD project, took an interest in the strain. Thus, together with scientists at BIOPOLIS they began to define what was to become the first commercial product designed for the celiac community, incorporating the probiotic strain Bifidobacterium longum ES1.